PRMT1 and neoplasm: Importantly, the PRMT1 inhibitor GSK3368715 has entered phase I clinical trials, and its main tumor types include pancreatic cancer, non-small cell lung cancer, bladder tumors, and blood tumors of diffuse large B-cell lymphoma.